Nonprofit under pressure to make new TB drug affordable

Authorities warn that antibiotic-resistant infections rank high, if not at the top, of public and global health concerns. TB offers a prime...

Biogen points to M&A power as Wall Street presses for less risky programs

Dive Insight: Biogen took the most severe blow in its history last month, losing more than $20 billion in market capitalization on the announcement that the...

Wave delays key data readout for Huntington’s therapy

Investors reacted negatively to the pushed-back readouts, sending shares of the Singapore-based biotech down nearly 20% between Tuesday's market close and Wednesday's. Wall Street analysts, meanwhile,...

Intra-Cellular’s depression drug goes 1 for 2 in Phase 3 studies

Intra-Cellular's success and failure demonstrate the difficulty of developing psychiatric drugs. Unqualified clinical success in depression is particularly challenging, as high placebo responses can...
Dive Insight: While California sequencing company Illumina is larger, Oxford's kept itself relevant and recently attracted new cash to fund an expansion. Amgen's seen the sequencing...
Clovis' Rubraca (rucaparib) was given an accelerated approval in December 2016 for advanced and pretreated ovarian cancer. However, the Colorado-based biotech still lags behind...
Alzheimer's drug development is notoriously difficult, exemplified by the fact there are no therapies approved to treat the underlying disease. That's not for a lack...

Follow RXMonthly

News

Clinical biomarkers expected to lift R&D productivity: Iqvia

Pharma's recent slump in R&D productivity — the rate of success in relation to the time and effort invested in drug development — has...

Pfizer, Novartis partner in hunt to find drugs for...

Neither Pfizer or Novartis are among the handful of companies at the leading edge of NASH drug development, which has yet to advance a...

Hunting productivity, drugmakers pitch new ‘pillars’ of R&D

SAN FRANCISCO — Developing new medicines isn't a resource-efficient endeavor. Estimates vary, but most molecules selected to begin clinical development won't end up on pharmacy...

Catalent to buy Paragon for $1.2B as gene therapy...

Biologics have been a business boon to contract manufacturers, Catalent included. Large-molecule drugs are such a focus, in fact, that last year Catalent split its...

Latest articles

CMS chief declines to provide details on Trump healthcare plan

The administration faces increasing pressure to release a concrete healthcare plan as Democratic presidential candidates are eager to keep the national conversation focused...

Roche cancer drug the 3rd approved for pan-tumor use

Aimed at the molecular catalysts of tumor growth, targeted therapies are treatment mainstays across a wide range of cancer types. 

Novo faces shareholder suit over insulin sales disclosures

Novo is best known for its insulin products like Levemir (insulin detemir) and Tresiba (insulin degludec), as well as other diabetes treatments like...

Celgene wins approval for drug key to Bristol buyout

Approval of Inrebic, which was previously known as fedratinib, is the first domino to fall in Bristol-Myers bet on Celgene's product pipeline. 

Subscribe to our newsletter